{"id":"placebo-to-tolterodine","safety":{"commonSideEffects":[{"rate":"35-40","effect":"Dry mouth"},{"rate":"5-7","effect":"Headache"},{"rate":"15-20","effect":"Constipation"},{"rate":"2-4","effect":"Dizziness"},{"rate":"1-3","effect":"Blurred vision"},{"rate":"1-2","effect":"Urinary retention"}]},"_chembl":{"chemblId":"CHEMBL1722209","moleculeType":"Small molecule","molecularWeight":"475.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tolterodine selectively blocks M3 muscarinic receptors on the detrusor muscle of the bladder, preventing acetylcholine-induced contractions. This reduces the frequency and urgency of urination and increases bladder capacity. The drug has relative selectivity for bladder M3 receptors over salivary gland M3 receptors, which may reduce certain anticholinergic side effects compared to non-selective agents.","oneSentence":"Tolterodine is a muscarinic M3 receptor antagonist that reduces bladder muscle contractions to treat overactive bladder symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:53.917Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with symptoms of urge incontinence, urgency, and frequency"}]},"trialDetails":[{"nctId":"NCT05362292","phase":"PHASE4","title":"TReating Incontinence for Underlying Mental and Physical Health","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2022-10-04","conditions":"Urinary Incontinence, Urge, Urinary Incontinence, Overactive Bladder","enrollment":270},{"nctId":"NCT00688688","phase":"PHASE3","title":"Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-04-25","conditions":"Urinary Bladder, Overactive","enrollment":2792},{"nctId":"NCT00689104","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-04-28","conditions":"Urinary Bladder, Overactive","enrollment":2336},{"nctId":"NCT01604928","phase":"PHASE2","title":"Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2004-04-05","conditions":"Urinary Bladder, Overactive","enrollment":260},{"nctId":"NCT00966004","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-07-24","conditions":"Urinary Bladder, Overactive","enrollment":1139},{"nctId":"NCT04500860","phase":"PHASE1","title":"Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2020-12-01","conditions":"Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence","enrollment":90},{"nctId":"NCT00852696","phase":"NA","title":"Over Active Bladder Patients Having Sling Surgery","status":"TERMINATED","sponsor":"Cleveland Clinic Florida","startDate":"2008-02","conditions":"Overactive Bladder","enrollment":1},{"nctId":"NCT03583372","phase":"PHASE3","title":"An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).","status":"COMPLETED","sponsor":"Urovant Sciences GmbH","startDate":"2018-06-14","conditions":"Overactive Bladder","enrollment":506},{"nctId":"NCT03492281","phase":"PHASE3","title":"A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Urovant Sciences GmbH","startDate":"2018-03-26","conditions":"Overactive Bladder","enrollment":1530},{"nctId":"NCT01302938","phase":"PHASE4","title":"Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-03","conditions":"Overactive Bladder","enrollment":18},{"nctId":"NCT00143377","phase":"PHASE4","title":"Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-09","conditions":"Urinary Incontinence","enrollment":600},{"nctId":"NCT00137397","phase":"PHASE4","title":"A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-11","conditions":"Urinary Incontinence","enrollment":80},{"nctId":"NCT00411437","phase":"PHASE4","title":"Effects Of Detrol LA On Memory And Cognition In Elderly Population","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-12","conditions":"Memory, Cognition","enrollment":220},{"nctId":"NCT00147654","phase":"PHASE4","title":"Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-11","conditions":"Urinary Incontinence","enrollment":830},{"nctId":"NCT00282932","phase":"PHASE4","title":"Detrol LA In Men With Overactive Bladder.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-01","conditions":"Overactive Bladder (OAB)","enrollment":600},{"nctId":"NCT02138747","phase":"PHASE4","title":"A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2014-07-24","conditions":"Overactive Bladder (OAB)","enrollment":376},{"nctId":"NCT01741454","phase":"PHASE4","title":"Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2012-11","conditions":"Ureteral Obstruction","enrollment":181},{"nctId":"NCT02436889","phase":"PHASE4","title":"Treatment of Incontinence Without Memory Problems","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-02","conditions":"Urge Incontinence, Urinary Incontinence, Urge","enrollment":23},{"nctId":"NCT01314872","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03-31","conditions":"Urinary Bladder, Overactive","enrollment":1395},{"nctId":"NCT01500382","phase":"PHASE1","title":"A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-27","conditions":"Overactive Bladder, Overactive Urinary Bladder","enrollment":4},{"nctId":"NCT01302054","phase":"PHASE4","title":"A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-05","conditions":"Urinary Bladder, Overactive","enrollment":990},{"nctId":"NCT00323635","phase":"PHASE4","title":"A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2006-04","conditions":"Urinary Incontinence","enrollment":19},{"nctId":"NCT00768521","phase":"PHASE1","title":"A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09-03","conditions":"Overactive Bladder","enrollment":20},{"nctId":"NCT02877901","phase":"PHASE2, PHASE3","title":"Effect of Long Acting Anticholinergic on Nocturnal Incontinence After Radical Cystectomy and Orthotopic Neobladder","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2016-05","conditions":"Nocturnal Incontinence","enrollment":120},{"nctId":"NCT02485067","phase":"PHASE3","title":"Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2015-01","conditions":"Overactive Bladder","enrollment":384},{"nctId":"NCT01050114","phase":"PHASE3","title":"OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER","status":"UNKNOWN","sponsor":"Christopher Patrick Smith","startDate":"2013-08","conditions":"Overactive Bladder","enrollment":36},{"nctId":"NCT00564226","phase":"PHASE2","title":"SSR240600C Treatment in Women With Overactive Bladder","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-11","conditions":"Overactive Bladder","enrollment":345},{"nctId":"NCT01356355","phase":"PHASE2","title":"Study of Herbmed Plus in Ureteral Stent Discomfort","status":"COMPLETED","sponsor":"Dr .S.B.PATANKAR","startDate":"2012-04","conditions":"Ureteral Stent Discomfort","enrollment":140},{"nctId":"NCT00939120","phase":"PHASE4","title":"Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)","status":"COMPLETED","sponsor":"Siami, Paul F., M.D.","startDate":"2009-07","conditions":"Benign Prostatic Hyperplasia (BPH)","enrollment":46},{"nctId":"NCT00444925","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-04","conditions":"Overactive Bladder","enrollment":1712},{"nctId":"NCT01089751","phase":"PHASE4","title":"Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-03","conditions":"Overactive Bladder","enrollment":322},{"nctId":"NCT00703703","phase":"PHASE1","title":"Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-05","conditions":"Healthy","enrollment":117},{"nctId":"NCT00876421","phase":"PHASE2","title":"Study of ONO-8539 in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2009-04","conditions":"Overactive Bladder","enrollment":435},{"nctId":"NCT00611026","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-02","conditions":"Overactive Bladder","enrollment":2417},{"nctId":"NCT00553657","phase":"PHASE1","title":"The Study To Test The Effect of Standardization Of Fluid Intake In Female Patients With Overactive Bladder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08","conditions":"Overactive Bladder","enrollment":55},{"nctId":"NCT00413790","phase":"PHASE4","title":"Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-11","conditions":"Healthy","enrollment":162},{"nctId":"NCT00439192","phase":"PHASE2","title":"ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)","status":"TERMINATED","sponsor":"elbion AG","startDate":"2007-02","conditions":"Overactive Bladder, Urinary Incontinence","enrollment":275}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to Tolterodine","genericName":"Placebo to Tolterodine","companyName":"Astellas Pharma Inc","companyId":"astellas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tolterodine is a muscarinic M3 receptor antagonist that reduces bladder muscle contractions to treat overactive bladder symptoms. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}